Literature DB >> 19818307

Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.

Mangesh Pagadala1, Claudia O Zein, Arthur J McCullough.   

Abstract

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the United States. The development of non-alcoholic steatohepatitis increases the risk for cirrhosis and its complications. The gold standard for diagnosis is liver biopsy, the costs and risks of which make it impractical. Some demographic factors, blood tests, and imaging studies can be used to predict a higher risk of steatohepatitis or advanced fibrosis, but are of limited sensitivity and specificity. More accurate predictors and scoring systems would allow identifying who would benefit most from liver biopsy and monitor disease progression and response to therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818307     DOI: 10.1016/j.cld.2009.07.011

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  13 in total

1.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

2.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

3.  Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease.

Authors:  Nicola Vitturi; Marta Soattin; Fabio De Stefano; Daniela Vianello; Alberto Zambon; Mario Plebani; Luca Busetto
Journal:  Eat Weight Disord       Date:  2014-08-17       Impact factor: 4.652

Review 4.  Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Melinda Frye; Michael J Pagliassotti
Journal:  Antioxid Redox Signal       Date:  2011-04-26       Impact factor: 8.401

5.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

6.  A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.

Authors:  Yoshio Sumida; Masato Yoneda; Hideyuki Hyogo; Kanji Yamaguchi; Masafumi Ono; Hideki Fujii; Yuichiro Eguchi; Yasuaki Suzuki; Shunsuke Imai; Kazuyuki Kanemasa; Koji Fujita; Kazuaki Chayama; Kohichiroh Yasui; Toshiji Saibara; Norifumi Kawada; Kazuma Fujimoto; Yutaka Kohgo; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2010-09-15       Impact factor: 7.527

Review 7.  Pathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-03-02       Impact factor: 46.802

8.  Association between diabetes mellitus and cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; An Pan; Wan-Cheng Chow; Jian-Min Yuan; Woon-Puay Koh
Journal:  Liver Int       Date:  2016-09-16       Impact factor: 5.828

9.  Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease.

Authors:  Jacob M Haus; Thomas P J Solomon; Karen R Kelly; Ciaran E Fealy; Emily L Kullman; Amanda R Scelsi; Lan Lu; Mangesh R Pagadala; Arthur J McCullough; Chris A Flask; John P Kirwan
Journal:  J Clin Endocrinol Metab       Date:  2013-04-24       Impact factor: 5.958

Review 10.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.

Authors:  Licia Polimeni; Maria Del Ben; Francesco Baratta; Ludovica Perri; Fabiana Albanese; Daniele Pastori; Francesco Violi; Francesco Angelico
Journal:  World J Hepatol       Date:  2015-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.